Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 19/20 | 0.52 |
| ▸ | PPARA | Q07869 | 17/20 | 0.52 |
| ▸ | PPARD | Q03181 | 8/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL542868 | 0.93 | PPARG (0.61) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL542907 | 0.87 | PPARA (0.50) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL543143 | 0.86 | PPARG (0.54) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL6076509 | 0.83 | PPARG (0.54) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL6075840 | 0.82 | PPARG (0.56) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL543817 | 0.81 | PGR (0.70) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL543221 | 0.81 | PGR (0.70) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL543149 | 0.81 | PPARG (0.56) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL543892 | 0.81 | PPARA (0.60) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL6075593 | 0.80 | PPARG (0.51) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110598-B2 | (+-) Ethyl 3-{4-[2-(pyrrol-1-yl)ethoxy]phenyl}-2-ethoxypropanoate; hyperlipidaemia, hypercholesteremia, hyperglycemia, obesity, impaired glucose intolerance, leptin resistance, insulin resistance, reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids in the plasma | CADILA HEALTHCARE LIMITED (IN) | 2012-02-07 | — | — | US | claimed |
| US-20080188402-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE | CADILLA HEALTHCARE LIMITED (IN) | 2008-08-07 | — | — | US | claimed |
| US-6987123-B2 | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2006-01-17 | — | — | US | claimed |
| US-20040186099-A1 | Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | LOHRAY BRAJ BHUSHAN (IN) | 2004-09-23 | — | — | US | claimed |
| US-20030236254-A1 | Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2003-12-25 | — | — | US | claimed |
| US-20030199498-A1 | Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED | 2003-10-23 | — | — | US | claimed |
| US-8110598-B2 | (+-) Ethyl 3-{4-[2-(pyrrol-1-yl)ethoxy]phenyl}-2-ethoxypropanoate; hyperlipidaemia, hypercholesteremia, hyperglycemia, obesity, impaired glucose intolerance, leptin resistance, insulin resistance, reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids in the plasma | CADILA HEALTHCARE LIMITED (IN) | 2012-02-07 | — | — | US | disclosed |
| US-20080188402-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE | CADILLA HEALTHCARE LIMITED (IN) | 2008-08-07 | — | — | US | disclosed |
| US-7041837-B2 | Heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILLA HEALTHCARE LIMITED (IN) | 2006-05-09 | — | — | US | disclosed |
| US-6987123-B2 | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2006-01-17 | — | — | US | disclosed |
| US-20030236254-A1 | Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2003-12-25 | — | — | US | disclosed |
| US-20030199498-A1 | Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199498-A1 | Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | CYP11B2, CYP11B1, MAPT | PPARG 726/4885PPARA 624/4885PPARD 239/4885 |
| US-20040186099-A1 | Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | CYP11B2, CYP11B1, MAPT | PPARG 726/4885PPARA 624/4885PPARD 239/4885 |
| US-20030236254-A1 | Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | LIPA, LIPC, CYP46A1 | PPARG 129/4885PPARA 68/4885PPARD 143/4885 |
| US-20080188402-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE | CYP11B2, MAPT, CYP11B1 | PPARG 546/4885PPARA 483/4885PPARD 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.